Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Science Advances|March 29, 2023
ATP-releasing SWELL1 channel in spinal microglia contributes to neuropathic painJiachen Chu, Junhua Yang, Yuan Zhou, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Puromycin-sensitive aminopeptidase acts as an inhibitory auxiliary subunit of volume-regulated anion channelsWenqiang Zheng, Tatsuya Hagino, Hao Wang, et al.
Molecular Cell|December 10, 2025
Puromycin-sensitive aminopeptidase acts as an inhibitory auxiliary subunit of volume-regulated anion channels and regulates cGAMP transportWenqiang Zheng, Tatsuya Hagino, Hao Wang, et al.
American Journal of Physiology. Renal Physiology|March 7, 2019
Loss of <i>miR-17~92</i> results in dysregulation of <i>Cftr</i> in nephron progenitorsYu Leng Phua, Kevin Hong Chen, Shelby L Hemker, et al.
Biomacromolecules|September 27, 2017
Heparin Binding to an Engineered Virus-like Nanoparticle AntagonistHo Yong Cheong, Myles Groner, Kevin Hong, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentAlbert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
Future Oncology (London, England)|May 10, 2025
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myelomaSagar Lonial, Meletios A Dimopoulos, Jesus G Berdeja, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 17, 2010
Safety and efficacy of thrombin-JMI: a multidisciplinary expert group consensusMohit Bhandari, Frederick A Ofosu, Nigel Mackman, et al.
Leukemia & Lymphoma|June 9, 2016
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trialsDavid S Siegel, Katja C Weisel, Meletios A Dimopoulos, et al.
Molecular Cancer Therapeutics|April 18, 2009
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90Karen Lundgren, Hong Zhang, John Brekken, et al.
Pageof 5